1.GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults. Retrieved June 10, 2022, from https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-pivotal-phase-iii-data-for-its-respiratory-syncytial-virus-rsv-vaccine-candidate-for-older-adults/.
2.Drysdale S B , Barr R S , Rollier C S , et al. Priorities for developing respiratory syncytial virus vaccines in different target populations[J]. Science Translational Medicine, 2020, 12(535):eaax2466.
3.Battles M B , Mclellan J S . Respiratorysyncytial virus entry and how to block it[J]. Nature Public Health EmergencyCollection, 2019, 17(4).